Skip to main content

Non-Small Cell Lung Cancer Topic Center

Interactive Features

news


News
06/09/2025
Juliet Gallagher
A recent retrospective study using the National Cancer Database suggests that Medicaid expansion under the Affordable Care Act (ACA) may improve access to local therapy—surgery or stereotactic body radiation therapy (SBRT)—for patients with...
A recent retrospective study using the National Cancer Database suggests that Medicaid expansion under the Affordable Care Act (ACA) may improve access to local therapy—surgery or stereotactic body radiation therapy (SBRT)—for patients with...
A recent retrospective study...
06/09/2025
First Report Managed Care
News
05/13/2025
Lisa Kuhns, PhD, MD
First-line (1L) treatment with immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, is the most frequently used and costliest systemic therapy for metastatic non-small cell lung cancer (NSCLC) patients without...
First-line (1L) treatment with immune checkpoint inhibitors (ICIs), particularly in combination with chemotherapy, is the most frequently used and costliest systemic therapy for metastatic non-small cell lung cancer (NSCLC) patients without...
First-line (1L) treatment with...
05/13/2025
First Report Managed Care
News
04/23/2025
Grace Taylor, MS, MA
Study finds extended survival with immunotherapy beyond disease progression for patients with non–small cell lung cancer.
Study finds extended survival with immunotherapy beyond disease progression for patients with non–small cell lung cancer.
Study finds extended survival...
04/23/2025
First Report Managed Care
News
04/11/2025
Lisa Kuhns, PhD, MD
Black patients with non-small cell lung cancer (NSCLC) in the US experience significantly worse care and outcomes compared with White patients, and these disparities are largely explained by exposure to structural racism across the health...
Black patients with non-small cell lung cancer (NSCLC) in the US experience significantly worse care and outcomes compared with White patients, and these disparities are largely explained by exposure to structural racism across the health...
Black patients with non-small...
04/11/2025
First Report Managed Care
News
12/09/2024
Jolynn Tumolo
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically...
12/09/2024
First Report Managed Care
News
11/05/2024
Hannah Musick
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
10/11/2024
Jolynn Tumolo
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was...
10/11/2024
First Report Managed Care
News
10/11/2024
Lisa Kuhns, PhD, MD
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the...
10/11/2024
First Report Managed Care
News
09/10/2024
Lisa Kuhns, PhD, MD
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results,...
09/10/2024
First Report Managed Care
News
08/21/2024
Lisa Kuhns, PhD, MD
Targeting CD38 may significantly enhance the efficacy of chemotherapy in patients with small cell lung cancer (SCLC), according to study results published in Frontiers in Immunology.
Targeting CD38 may significantly enhance the efficacy of chemotherapy in patients with small cell lung cancer (SCLC), according to study results published in Frontiers in Immunology.
Targeting CD38 may significantly...
08/21/2024
First Report Managed Care